Lorena Cuenca Bermejo

De Araujo FM, Frota AF, de Jesus LB, Macedo TC, Cuenca-Bermejo L, Sanchez-Rodrigo C, Ferreira KMS, de Oliveira JVR, de Fatima Dias Costa M, Segura-Aguilar J, Costa SL, Herrero MT, Silva VDA. Aminochrome Induces Neuroinflammation and Dopaminergic Neuronal Loss: A New Preclinical Model to Find Anti-inflammatory and Neuroprotective Drugs for Parkinson's Disease. Cell Mol Neurobiol. 2023 Jan;43(1):265-281. doi: 10.1007/s10571-021-01173-5. Epub 2022 Jan 6. PubMed PMID: 34988761.

AÑO: 2023; IF: 4.0

34988761

Herrero MT, Yuste JE, Cuenca-Bermejo L, Almela P, Arenas-Betancur L, De Pablos V, Gonzalez-Cuello A, Del Bel E, Navarro-Zaragoza J, Fernandez-Villalba E. 7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate. Open Biol. 2023 May;13(5):220370. doi: 10.1098/rsob.220370. Epub 2023 May 17. PubMed PMID: 37192671; PubMed Central PMCID: PMC10188238.

AÑO: 2023; IF: 7.124

37192671

Romo-Vaquero M, Fernandez-Villalba E, Gil-Martinez AL, Cuenca-Bermejo L, Espin JC, Herrero MT, Selma MV. Urolithins: potential biomarkers of gut dysbiosis and disease stage in Parkinson's patients. Food Funct. 2022 Jun 6;13(11):6306-6316. doi: 10.1039/d2fo00552b. PubMed PMID: 35611932.

AÑO: 2022; IF: 6.1

35611932

Goncalves VC, Cuenca-Bermejo L, Fernandez-Villalba E, Martin-Balbuena S, da Silva Fernandes MJ, Scorza CA, Herrero MT. Heart Matters: Cardiac Dysfunction and Other Autonomic Changes in Parkinson's Disease. Neuroscientist. 2022 Dec;28(6):530-542. doi: 10.1177/1073858421990000. Epub 2021 Feb 15. PubMed PMID: 33583239.

AÑO: 2022; IF: 5.6

33583239

de Araujo FM, Cuenca-Bermejo L, Fernandez-Villalba E, Costa SL, Silva VDA, Herrero MT. Role of Microgliosis and NLRP3 Inflammasome in Parkinson's Disease Pathogenesis and Therapy. Cell Mol Neurobiol. 2022 Jul;42(5):1283-1300. doi: 10.1007/s10571-020-01027-6. Epub 2021 Jan 2. PubMed PMID: 33387119.

AÑO: 2022; IF: 4.0

33387119